臨床泌尿器科59巻3号

2005年03月発行

綜説

転移を有する尿路上皮癌に対する治療方針

著者： 篠原信雄¹

所属機関： ¹北海道大学大学院医学研究科腎泌尿器外科

ページ範囲：P.183 - P.192

文献概要

要旨　種々の試みにもかかわらず，遠隔転移を有する尿路上皮癌の予後は不良である。本稿では，転移を有する尿路上皮癌の予後改善にわれわれが取りえる道として，MVAC療法など全身化学療法後の残存転移巣に対する治療方針を，転移巣切除や放射線治療を含めた集学的治療に焦点を当て，解説した。現状では，長期生存についてはまだまだ困難な状況にあるが，集学的治療により，ある一定の割合で長期生存を期待しえる症例の存在があることが明らかになった。ただ，それらを適切に判断する指標は明確でなく，その時々の状況や患者の意向を十分に加味し，各種治療をアレンジし実施することが必要である。これらの結果をまとめ，適切な治療方針を確立する必要があると思われる。

参考文献

1）Sternberg CN, Yagoda A, Scher HI, et al：Preliminary results of methotrexate, vinblastine, adriamycin and cisplatin（M-VAC）in advanced urothelial tumors. J Urol 133：403-407, 1985

2）Sternberg CN, Yagoda A, Scher HI, et al：Methotrexate, vinblastine, doxorubicin, and cispltain for advanced transitional cell carcinoma of the urothelium. Cancer 64：2448-2458, 1989

3）Loehre Sr PJ, Einhorn LH, Elson PJ, et al：A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma：a cooperative group study. J Clin Oncol 10：1066-1073, 1992

4）Saxman SB, Loehrer PJ, Propert K, et al：Long-term follow-up of phaseⅢ Intergroup study of MVAC vs. cisplatin in metastatic urothelial carcinoma：a cooperative group study. J Clin Oncol 15：2564-2569, 1997

5）Dodd PM, McCaffrey JA, Mazumdar M, et al：Dose-intensive M-VAC（DI-M-VAC）does not impact survival relative to standard M-VAC in patients with transitional cell carcinoma（TCC）［abstract］. Proc ASCO 17：317a（1223）, 1998

6）Loehrer Sr PJ, Elson P, Dreicer R, et al：Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma：an Eastern Cooperative Group trial. J Clin Oncol 12：483-488, 1994

7）Sternberg CM, De Mulder P, Fossa S, et al：Interim toxicity analysis of a randomized trial in advanced urothelial tract tumors of high-dose intensity MVAC chemotherapy and recombinant human granulocyte colony stimulating factor（G-CSF）versus classic MVAC chemotherapy. Proc ASCO 16：320a（1140）, 1997

8）Sternberg CN, de Mulder PH, Schornagel J, et al：Randomized phaseⅢ trial in advanced urothelial tract tumors of high dose intensity MVAC chemotherapy and G-CSF versus classic MVAC. Proc ASCO 19：329a（1292）, 2000

9）羽渕友則，大山　力：進行尿路上皮癌に対する化学療法：最近の話題．臨泌58：189-196，2004

10）鈴木　信，篠原信雄，原林　透，他：進行性尿路上皮癌に対するTIN（Paclitaxel. Ifosfamide, Nedaplatin）療法．癌と化学療法31：561-565，2004

11）Babian RJ, Johnson DE, Llamas L, et al：Metastases from transitional cell carcinoma of the urinary bladder. Urology 166：142-144, 1980

12）宮永直人，赤座英之：悪性新生物　膀胱癌．日本臨牀59：379-385，2001

13）垣添忠生，藤元博之：全国膀胱癌患者登録調査報告：1988～96年症例のまとめ．児玉哲郎（編）：厚生労働省がん研究助成金9-1　主要がんの全国登録に基づく患者情報の解析と活用に関する研究　研究報告書．pp123-131，平成12年度

14）Von der Maase H, Hansen SW, Roberts JT, et al：Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicine, and cisplatin in advanced or metastatic bladder cancer：results of a large, randomized, multinational, multicenter, phaseⅢstudy. J Clin Oncol 18：3068-3077, 2000

15）Bellmunt J, Guillem V, Paz-Arez L, et al：PhaseⅠ-Ⅱ study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. J Clin Oncol 18：3247-3255, 2000

16）Dodd PM, McCaffrey JA, Herr H, et al：Outcome of postchemotherapy surgery after treatment with methotrexate, vinbilastine, doxorubicin and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. J Clin Oncol 17：2546-2552, 1999

17）Sweeney CJ, Williams SD, Finch DE, et al：A phaseⅡ study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium. Cancer 86：514-518, 1999

18）de Mulder P, Theodore C, Sella A, et al：PhaseⅡ EORTC-trial with 5-fluorouracil（5FU）, cisplatin（C）and interferon-α（IFN-α2B）as second line treatment of advanced transitional cell cancer（TCC）of the urothelial tract. Ann Oncol 11：1391-1394, 2000

19）Meluch AA, Greco FA, Burris HAⅢ, et al：Paclitaxel and gemcitabine chemotherapy for advanced transitional cell carcinoma of the urothelial tract：a phaseⅡ trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 19：3018-3024, 2001

20）Sternberg CN, Calabro F, Pizzocaro G, et al：Chemotherapy with an every-2 week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 92：2993-2998, 2001

21）Miller RS, Freiha FS, Reese JH, et al：Cisplatin, methoterexate and vinblastine plus surgical restaging for patients with advanced transitional cell carcinoma of the urothelium. J Urol 150：65-69, 1993

22）Siefker-Radtke AO, Walsh GL, Pisters LL, et al：Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson Experience. J Urol 171：145-148, 2004

23）Dimopoulos MA, Finn L and Logothetis CJ：Pattern of failure and survival of patients with metastatic urothelial tumors relapsing after cisplatin-based chemotherapy. J Urol 151：598-601, 1994

24）Sugiura H, Morikawa T, Kaji M, et al：Long-term benefits for the quality of life after video-assisted thoracoscopic lobectomy in patients with lung cancer. Surg Laparosc Endosc Percutan Tech 9：403-408, 1999

25）Hack M, Gerber M, Dilk O, et al：Long-term survival of patients with metastatic transitional cell carcinoma treated with a combined-modality approach of chemotherapy and metastatectomy. J Urol 171：313a, 2004

26）Palese MA, Su LM and Kavoussi LR：Laparoscopic retroperitoneal lymph node dissection after chemotherapy. Urology 60：130-134, 2002

27）Steiner H, Peschel R, Janetschek G, et al：Long-term results of laparoscopic retroperitoneal lymph node dissection：a single-center 10-year experi-ence. Urology 63：550-555, 2004

28）Otto T, Krege S, Suhr J, et al：Impact of surgical resection of bladder cancer metastases refractory to systemic therapy on performance score：a phaseⅡ trial. Urology 57：55-59, 2001

29）Rosenstin M, Wallner K Scher H, et al：Brain metastases from transitional cell carcinoma of the bladder. J Urol 149：480-483, 1993

30）Anderson RS, El-Mahdi AM, Kuban DA, et al：Brain metastases from transitional carcinoma of urinary bladder. Urology 39：17-20, 1992

31）Vikram B, Chadha M, Malamud SC, et al：Rapidly alternating chemotherapy and radiotherapy instead of cystectomy for the treatment of muscle-invasive carcinoma of the urinary bladder：long term results of a pilot study. Cancer 82：918-922, 1998

32）Shimizu S, Shirato H, Ogura S, et al：Detection of lung tumor movement in real-time tumor-tracking radiotherapy. Int J Radiat Oncol Biol Phys 51：304-310, 2001

33）Harada T, Shirato H, Ogura S, et al：Real-time tumor-tracking radiation therapy for lung carcinoma by the aid of insertion of a gold marker using bronchofiberscopy. Cancer 95：1720-1727, 2002

34）Kuroda N, Hayashi Y, Nishida Y, et al：Combined small and transitional cell carcinoma of the bladder with CA19-9 production. Pathol Int 49：462-467, 1999

35）Cook AM, Huddart RA, Jay G, et al：The utility of tumor markers in assessing the response to chemotherapy in advanced bladder cancer. Br J Cancer 82：1952-1957, 2000

36）Kosuda S, Klson PV, Greenough R, et al：Preliminary assessment of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with bladder cancer. Eur J Nucl Med 24：615-620, 1997

37）Hofer C, Kubler H, Hartung R, et al：Diagnosis and monitoring of urological tumors using positron emission tomography. Eur Urol 40：481-487, 2001